SG11201401726VA - Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as parp inhibitors - Google Patents
Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as parp inhibitorsInfo
- Publication number
- SG11201401726VA SG11201401726VA SG11201401726VA SG11201401726VA SG11201401726VA SG 11201401726V A SG11201401726V A SG 11201401726VA SG 11201401726V A SG11201401726V A SG 11201401726VA SG 11201401726V A SG11201401726V A SG 11201401726VA SG 11201401726V A SG11201401726V A SG 11201401726VA
- Authority
- SG
- Singapore
- Prior art keywords
- penta
- parp inhibitors
- dihydrodiazepinocarbazolones
- cyclic
- fused tetra
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2011/085148 WO2013097225A1 (en) | 2011-12-31 | 2011-12-31 | Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as parp inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201401726VA true SG11201401726VA (en) | 2014-10-30 |
Family
ID=48696280
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201401726VA SG11201401726VA (en) | 2011-12-31 | 2011-12-31 | Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as parp inhibitors |
Country Status (29)
| Country | Link |
|---|---|
| US (4) | US9260440B2 (en) |
| EP (2) | EP3315500B1 (en) |
| JP (1) | JP6034877B2 (en) |
| KR (1) | KR101716012B1 (en) |
| CN (2) | CN103703004B (en) |
| AU (1) | AU2011384858B2 (en) |
| BR (1) | BR112014012628B8 (en) |
| CA (1) | CA2856309C (en) |
| CY (1) | CY1119804T1 (en) |
| DK (1) | DK2797921T3 (en) |
| EA (1) | EA027533B1 (en) |
| ES (1) | ES2645814T3 (en) |
| HK (1) | HK1192233A1 (en) |
| HR (1) | HRP20171883T1 (en) |
| HU (1) | HUE035153T2 (en) |
| IL (1) | IL233365A (en) |
| IN (1) | IN2014DN06169A (en) |
| LT (1) | LT2797921T (en) |
| ME (1) | ME02855B (en) |
| MX (1) | MX353578B (en) |
| NO (1) | NO2797921T3 (en) |
| NZ (1) | NZ624063A (en) |
| PL (1) | PL2797921T3 (en) |
| PT (1) | PT2797921T (en) |
| RS (1) | RS56616B1 (en) |
| SG (1) | SG11201401726VA (en) |
| SI (1) | SI2797921T1 (en) |
| WO (1) | WO2013097225A1 (en) |
| ZA (1) | ZA201405560B (en) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9260440B2 (en) | 2011-12-31 | 2016-02-16 | Beigene, Ltd. | Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as PARP inhibitors |
| JP6082409B2 (en) | 2012-03-07 | 2017-02-15 | インスティチュート オブ キャンサー リサーチ：ロイヤル キャンサー ホスピタル | 3-Aryl-5-substituted isoquinolin-1-one compounds and therapeutic uses thereof |
| US9611223B2 (en) | 2013-09-11 | 2017-04-04 | Institute Of Cancer Research: Royal Cancer Hospital (The) | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use |
| CN107922425B (en) * | 2015-08-25 | 2021-06-01 | 百济神州有限公司 | Methods of preparing PARP inhibitors, crystalline forms and uses thereof |
| WO2017172957A1 (en) | 2016-04-01 | 2017-10-05 | Kalyra Pharmaceuticals, Inc. | Estrogen receptor modulators |
| WO2018059437A1 (en) | 2016-09-27 | 2018-04-05 | Beigene, Ltd. | Treatment cancers using combination comprising parp inhibitors |
| WO2018157794A1 (en) * | 2017-02-28 | 2018-09-07 | Beigene, Ltd. | Crystalline forms of salts of fused tera or penta-cyclic dihydrodiazepinocarazolones, and uses thereof |
| CN106883232B (en) | 2017-03-31 | 2019-01-22 | 苏州康润医药有限公司 | A kind of derivative and the preparation method and application thereof of non-that alkene -3- ketone of azepine |
| EP3654985A4 (en) * | 2017-07-17 | 2021-04-07 | BeiGene, Ltd. | Treatment cancers using a combination comprising parp inhibitors, temozolomide and/or radiation therapy |
| EP3801550A4 (en) * | 2018-06-01 | 2022-02-16 | BeiGene, Ltd. | Maintenance therapy of a parp inhibitor in treating gastric cancer |
| CN113004279B (en) * | 2019-05-10 | 2023-01-06 | 百济神州(苏州)生物科技有限公司 | Method for controlling water content of PARP inhibitor-containing sesquihydrate product |
| CN113402502B (en) * | 2019-05-16 | 2022-10-14 | 百济神州(苏州)生物科技有限公司 | Material combination system for preparing PARP inhibitor intermediate |
| JP2022534093A (en) | 2019-05-31 | 2022-07-27 | ベイジーン リミテッド | PARP inhibitor pellet formulation and its preparation method |
| WO2021026153A1 (en) | 2019-08-06 | 2021-02-11 | Recurium Ip Holdings, Llc | Estrogen receptor modulators for treating mutants |
| WO2021046014A1 (en) | 2019-09-03 | 2021-03-11 | Teva Czech Industries S.R.O | Solid state forms of pamiparib and process for preparation thereof |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE445326B (en) | 1983-04-05 | 1986-06-16 | Malmstroem Anders E H | SET AND DEVICE FOR THE PREVENTION OF WALL TURNS |
| US6799298B2 (en) | 1998-03-11 | 2004-09-28 | Overture Services, Inc. | Technique for locating an item of interest within a stored representation of data |
| EP1140936B1 (en) | 1999-01-11 | 2004-03-17 | Agouron Pharmaceuticals, Inc. | Tricyclic inhibitors of poly(adp-ribose) polymerases |
| CA2430363C (en) | 2000-12-01 | 2010-04-13 | Guilford Pharmaceuticals Inc. | Compounds and their uses |
| US6423705B1 (en) | 2001-01-25 | 2002-07-23 | Pfizer Inc. | Combination therapy |
| US6906096B2 (en) | 2002-06-28 | 2005-06-14 | Irm Llc | 4,7-Disubstituted indoles and methods of making |
| AU2004203977B2 (en) | 2003-01-09 | 2010-06-17 | Pfizer Inc. | Diazepinoindole derivatives as kinase inhibitors |
| AU2004242947B2 (en) | 2003-05-28 | 2010-04-29 | Eisai Inc. | Compounds, methods and pharmaceutical compositions for inhibiting PARP |
| CA2648369A1 (en) | 2006-04-04 | 2007-10-11 | Pfizer Products Inc. | Polymorphic forms of (2r,z)-2-amino-2-cyclohexyl-n-(5-(1-methyl-1h-pyrazol-4?l)-1-oxo-2,6-dihydro-1h-[1,2]diazepino[4,5,6-cd]indol-8-yl)acetamide |
| KR20080100838A (en) | 2006-04-04 | 2008-11-19 | 화이자 프로덕츠 인코포레이티드 | Combination therapy of (2r,z)-2-amino-2-cyclohexyl-n-(5-(1-methyl-1h-pyrazol-4-yl)-1-oxo-2,6-dihydro-1h-[1,2]diazepino[4,5,6-cd]indol-8-yl)acetamide |
| ES2524787T3 (en) | 2007-11-15 | 2014-12-12 | Msd Italia S.R.L. | Pyridazinone derivatives as PARP inhibitors |
| SI2767537T1 (en) * | 2008-08-06 | 2017-08-31 | Medivation Technologies, Inc. | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) |
| WO2011130661A1 (en) | 2010-04-16 | 2011-10-20 | Biomarin Pharmaceutical Inc. | Methods of using dihydropyridophthalazinone inhibitors of poly (adp-ribose)polymerase (parp) |
| US9260440B2 (en) | 2011-12-31 | 2016-02-16 | Beigene, Ltd. | Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as PARP inhibitors |
| JP6623353B2 (en) | 2013-09-13 | 2019-12-25 | ベイジーン スウィッツァーランド ゲーエムベーハー | Anti-PD-1 antibodies and their use for therapy and diagnosis |
| TWI726608B (en) | 2014-07-03 | 2021-05-01 | 英屬開曼群島商百濟神州有限公司 | Anti-pd-l1 antibodies and their use as therapeutics and diagnostics |
| US9637488B2 (en) | 2015-01-29 | 2017-05-02 | Fuqiang Ruan | Heterocyclic compounds as inhibitors of class I PI3KS |
| CN107922425B (en) | 2015-08-25 | 2021-06-01 | 百济神州有限公司 | Methods of preparing PARP inhibitors, crystalline forms and uses thereof |
| WO2018059437A1 (en) | 2016-09-27 | 2018-04-05 | Beigene, Ltd. | Treatment cancers using combination comprising parp inhibitors |
| WO2018157794A1 (en) | 2017-02-28 | 2018-09-07 | Beigene, Ltd. | Crystalline forms of salts of fused tera or penta-cyclic dihydrodiazepinocarazolones, and uses thereof |
| EP3654985A4 (en) | 2017-07-17 | 2021-04-07 | BeiGene, Ltd. | Treatment cancers using a combination comprising parp inhibitors, temozolomide and/or radiation therapy |
-
2011
- 2011-12-31 US US14/369,374 patent/US9260440B2/en active Active
- 2011-12-31 NZ NZ624063A patent/NZ624063A/en unknown
- 2011-12-31 BR BR112014012628A patent/BR112014012628B8/en active IP Right Grant
- 2011-12-31 JP JP2014549295A patent/JP6034877B2/en active Active
- 2011-12-31 EP EP17183473.2A patent/EP3315500B1/en active Active
- 2011-12-31 HU HUE11878508A patent/HUE035153T2/en unknown
- 2011-12-31 NO NO11878508A patent/NO2797921T3/no unknown
- 2011-12-31 IN IN6169DEN2014 patent/IN2014DN06169A/en unknown
- 2011-12-31 CN CN201180072418.8A patent/CN103703004B/en active Active
- 2011-12-31 MX MX2014007840A patent/MX353578B/en active IP Right Grant
- 2011-12-31 LT LTEP11878508.8T patent/LT2797921T/en unknown
- 2011-12-31 SG SG11201401726VA patent/SG11201401726VA/en unknown
- 2011-12-31 CA CA2856309A patent/CA2856309C/en active Active
- 2011-12-31 CN CN201610603192.4A patent/CN106220635B/en active Active
- 2011-12-31 SI SI201131351T patent/SI2797921T1/en unknown
- 2011-12-31 KR KR1020147018104A patent/KR101716012B1/en active IP Right Grant
- 2011-12-31 WO PCT/CN2011/085148 patent/WO2013097225A1/en active Application Filing
- 2011-12-31 EA EA201491303A patent/EA027533B1/en not_active IP Right Cessation
- 2011-12-31 DK DK11878508.8T patent/DK2797921T3/en active
- 2011-12-31 ME MEP-2017-278A patent/ME02855B/en unknown
- 2011-12-31 RS RS20171228A patent/RS56616B1/en unknown
- 2011-12-31 AU AU2011384858A patent/AU2011384858B2/en active Active
- 2011-12-31 ES ES11878508.8T patent/ES2645814T3/en active Active
- 2011-12-31 PT PT118785088T patent/PT2797921T/en unknown
- 2011-12-31 PL PL11878508T patent/PL2797921T3/en unknown
- 2011-12-31 EP EP11878508.8A patent/EP2797921B1/en active Active
-
2014
- 2014-06-12 HK HK14105542.6A patent/HK1192233A1/en unknown
- 2014-06-25 IL IL233365A patent/IL233365A/en active IP Right Grant
- 2014-07-28 ZA ZA2014/05560A patent/ZA201405560B/en unknown
-
2016
- 2016-01-05 US US14/988,484 patent/US9617273B2/en active Active
-
2017
- 2017-04-05 US US15/479,958 patent/US10112952B2/en active Active
- 2017-11-16 CY CY20171101198T patent/CY1119804T1/en unknown
- 2017-12-04 HR HRP20171883TT patent/HRP20171883T1/en unknown
-
2018
- 2018-09-19 US US16/135,512 patent/US10501467B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1201266A1 (en) | Fused tetra or penta-cyclic pyridophthalazinones as parp inhibitors parp | |
| HRP20171883T1 (en) | Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as parp inhibitors | |
| HK1222647A1 (en) | Kinase inhibitors | |
| IL227252A0 (en) | Fused aminodihydrothiazine derivatives | |
| EP2683693A4 (en) | Rorgammat inhibitors | |
| EP2710007A4 (en) | Kinase inhibitors | |
| GB201101140D0 (en) | Fused aminodihydrothiazine derivatives | |
| AU341795S (en) | Paver | |
| HK1208450A1 (en) | Nampt inhibitors nampt | |
| AP3529A (en) | Hydroxymethylaryl-substituted pyrrolotriazines as alk1 inhibitors | |
| EP2702064A4 (en) | Kinase inhibitors | |
| HK1199873A1 (en) | Kinase inhibitors | |
| ZA201409497B (en) | Tetrahydroquinazolinone derivatives as parp inhibitors | |
| HK1209422A1 (en) | Fbxo3 inhibitors fbxo3 | |
| EP2847186A4 (en) | Substituted aminoquinazolines useful as kinases inhibitors | |
| PL2599920T3 (en) | Paver | |
| HK1208475A1 (en) | Methods for preventing biofilm formation | |
| GB201120494D0 (en) | Modified exonuclease | |
| GB201100924D0 (en) | Surfaces | |
| ZA201308697B (en) | Hydroxymethylaryl-substituted pyprolotriazines as alk1 inhibitors | |
| GB201116360D0 (en) | Glycobiological surfaces | |
| GB201110249D0 (en) | Laser | |
| GB201120474D0 (en) | Inhibitors | |
| GB201219306D0 (en) | Nampt inhibitors | |
| GB201100183D0 (en) | Fused aminodihydropyrimidone derivatives |